Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy.

摘要: PurposeOur previous work evaluated individual prognostic and predictive roles of TP53, KRAS, EGFR in non–small-cell lung cancer (NSCLC). In this analysis, we explore the TP53/KRAS TP53/EGFR comutations randomized trials adjuvant chemotherapy versus observation.Patients MethodsMutation analyses (wild-type [WT] mutant) for were determined blinded fashion multiple laboratories. Primary secondary end points pooled analysis overall survival disease-free survival. We role comutation all patients adenocarcinoma subgroup as well only through a multivariable Cox proportional hazards model stratified by trial.ResultsOf 3,533 with NSCLC, 1,181 (557 deaths) 404 (170 used analyses. For mutation status, no effect was observed (P = .61), whereas borderline pred...